Parathyroid hormone-related protein expression, in combination with nodal status, predicts bone metastasis and prognosis of breast cancer patients

Takagaki,Keiichi; Takashima,Tsutomu; Onoda,Naoyoshi; Tezuka,Kenji; Noda,Eiji; Kawajiri,Hidemi; Ishikawa,Tetsuro; Hirakawa,Kosei

doi:10.3892/etm.2012.521

Parathyroid hormone-related protein expression, in combination with nodal status, predicts bone metastasis and prognosis of breast cancer patients

Authors:
- Keiichi Takagaki
- Tsutomu Takashima
- Naoyoshi Onoda
- Kenji Tezuka
- Eiji Noda
- Hidemi Kawajiri
- Tetsuro Ishikawa
- Kosei Hirakawa
View Affiliations

Affiliations: Department of Surgical Oncology, Osaka City University Graduate School of Medicine, Osaka, Japan
Published online on: March 21, 2012 https://doi.org/10.3892/etm.2012.521
Pages: 963-968

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Parathyroid hormone-related protein (PTHrP) has been known to play an important role in the formation of metastatic lesions in the bone. However, there remains controversy over its practical role in predicting the occurrence of bone metastasis and the prognosis of breast cancer patients. In this study, we attempted to investigate the clinical value of PTHrP expression status in the primary lesions of breast cancer patients. We immunohistochemically investigated PTHrP expression in surgically resected specimens from 125 primary breast cancer patients whose clinicopathological background and long-term prognosis were available. Positive PTHrP staining was demonstrated in 79 (63.2%) tumors. PTHrP was expressed significantly more frequently in the tumors of premenopausal patients. Bone metastases were significantly more common in patients with T4 tumors, with a positive node, with distant metastasis and with PTHrP-positive tumors. Multivariate logistic analysis revealed positive PTHrP expression as an independent risk factor for predicting bone metastasis. PTHrP expression was significantly related to a shorter overall survival. Bone metastasis was found significantly more frequently (28.3%) in PTHrP- and node-positive cases than in double-negative cases, and the rate was more pronounced in postmenopausal cases (32.1%). Expression of PTHrP in primary lesions, in combination with positive nodal status, is indicative of an increased risk of bone metastasis in breast cancer patients.

View Figures

View References

1.	Coleman RE: Skeletal complications of malignancy. Cancer. 80:1588–1594. 1997. View Article : Google Scholar : PubMed/NCBI
2.	Mundy GR: Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2:584–593. 2002. View Article : Google Scholar : PubMed/NCBI
3.	Yoneda T and Hiraga T: Crosstalk between cancer cells and bone microenvironment in bone metastasis. Biochem Biophys Res Commun. 328:679–687. 2005. View Article : Google Scholar : PubMed/NCBI
4.	Suva LJ, Winslow GA, Wettenhall RE, et al: A parathyroid hormone-related protein implicated in malignant hypercalcemia: cloning and expression. Science. 237:893–896. 1987. View Article : Google Scholar : PubMed/NCBI
5.	Yin JJ, Selander K, Chirgwin JM, et al: TGF-β signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest. 103:197–206. 1999.
6.	Sanders JL, Chattopadhyay N, Kifor O, Yamaguchi T, Butters RR and Brown EM: Extracellular calcium-sensing receptor expression and its potential role in regulating parathyroid hormone-related peptide secretion in human breast cancer cell lines. Endocrinology. 141:4357–4364. 2000.
7.	Suda T and Takahashi N: Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev. 20:345–357. 1999. View Article : Google Scholar : PubMed/NCBI
8.	Rubens RD: Clinical aspects of bone metastases. Tumor Bone Diseases and Osteoporosis in Cancer Patients. Body JJ: Marcel Dekker, Inc.; Brussels: 85. 2000
9.	Southby J, Kissin MW, Danks JA, et al: Immunohistochemical localization of parathyroid hormone-related protein in human breast cancer. Cancer Res. 50:7710–7716. 1990.PubMed/NCBI
10.	Liapis H, Crouch EC, Grosso LE, Kitazawa S and Wick MR: Expression of parathyroidlike protein in normal, proliferative, and neoplastic human breast tissues. Am J Pathol. 143:1169–1178. 1993.PubMed/NCBI
11.	Kohno N, Kitazawa S, Fukase M, et al: The expression of parathyroid hormone-related protein in human breast cancer with skeletal metastases. Surg Today. 24:215–220. 1994. View Article : Google Scholar : PubMed/NCBI
12.	Downey SE, Hoyland J, Freemont AJ, Knox F, Walls J and Bundred NJ: Expression of the receptor for parathyroid hormone-related protein in normal and malignant breast tissue. J Pathol. 183:212–217. 1997. View Article : Google Scholar : PubMed/NCBI
13.	Henderson M, Danks J, Moseley J, et al: Parathyroid hormone-related protein production by breast cancers, improved survival, and reduced bone metastases. J Natl Cancer Inst. 93:234–237. 2001. View Article : Google Scholar : PubMed/NCBI
14.	Linforth R, Anderson N, Hoey R, et al: Coexpression of parathyroid hormone related protein and its receptor in early breast cancer predicts poor patient survival. Clin Cancer Res. 8:3172–3177. 2002.PubMed/NCBI
15.	Surowiak P, Dziegiel P, Matkowski R, Sopel M, Wojnar A, Kornafel J and Zabel M: Prognostic value of immunocytochemical determination of parathyroid hormone-related peptide expression in cells of mammary ductal carcinoma. Analysis of 7 years of the disease course. Virchows Arch. 442:245–251. 2003.
16.	Fleming NI, Trivett MK, George J, et al: Parathyroid hormone-related protein protects against mammary tumor emergence and is associated with monocyte infiltration in ductal carcinoma in situ. Cancer Res. 69:7473–7479. 2009. View Article : Google Scholar
17.	Bouizar Z, Spyratos F, Deytieux S, de Vernejoul MC and Jullienne A: Polymerase chain reaction analysis of parathyroid hormone-related protein gene expression in breast cancer patients and occurrence of bone metastasis. Cancer Res. 53:5076–5078. 1993.PubMed/NCBI
18.	Powell GJ, Southby J, Danks JA, et al: Localization of parathyroid hormone-related protein in breast cancer metastases: increased incidence in bone compared with other sites. Cancer Res. 51:3059–3061. 1991.PubMed/NCBI
19.	Kohno N, Kitazawa S, Sakoda Y, Kanbara Y, Furuya Y, Ohashi O and Kitazawa R: Parathyroid hormone-related protein in breast cancer tissues: relationship between primary and metastatic sites. Breast Cancer. 1:43–49. 1994. View Article : Google Scholar : PubMed/NCBI
20.	Guise TA, Yin JJ, Taylor SD, et al: Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest. 98:1544–1549. 1996. View Article : Google Scholar : PubMed/NCBI
21.	Thomas RJ, Guise TA, Yin JJ, Elliot J, Horwood NJ, Martin TJ and Gillespie MT: Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology. 140:4451–4458. 1999.PubMed/NCBI
22.	Tezuka K, Onoda N, Takashima T, Ishikawa T, Wakasa T, Wakasa K and Hirakawa K: Clinical significance of intra-tumoral sinusoidal structures showing lympho-endothelial immunoreactivity in breast cancer. Oncol Rep. 20:25–32. 2008.
23.	Henderson MA, Danks JA, Slavin JL, et al: Parathyroid hormone-related protein localization in breast cancers predict improved prognosis. Cancer Res. 66:2250–2256. 2006. View Article : Google Scholar : PubMed/NCBI
24.	Torricelli C, Fortino V, Capurro E, et al: Role of PTHrp and PTHrp-engaged pathways in MCF-7 cells migration/invasion. Matrix Biol. 25:104–111. 2006. View Article : Google Scholar : PubMed/NCBI
25.	Dittmer A, Vetter M, Schunke D, Span PN, Sweep F, Thomssen C and Dittmer J: Parathyroid hormone-related protein regulates tumor-relevant genes in breast cancer cells. J Biol Chem. 281:14563–14572. 2006. View Article : Google Scholar : PubMed/NCBI
26.	Braun S, Vogl FD, Naume B, et al: A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med. 353:793–802. 2005. View Article : Google Scholar : PubMed/NCBI
27.	Wulf GG, Jürgens B, Liersch T, et al: Reverse transcriptase/polymerase chain reaction analysis of parathyroid hormone-related protein for the detection of tumor cell dissemination in the peripheral blood and bone marrow of patients with breast cancer. J Cancer Res Clin Oncol. 123:514–521. 1997. View Article : Google Scholar
28.	Guise TA, Kozlow WM, Heras-Herzig A, Padalecki SS, Yin JJ and Cirgwin JM: Molecular mechanisms of breast cancer metastases to bone. Clin Breast Cancer. 5(Suppl 2): 46–53. 2005. View Article : Google Scholar : PubMed/NCBI
29.	Russell RG, Rogers MJ, Frith JC, et al: The pharmacology of bisphosphonates and new insights into their mechanisms of action. J Bone Miner Res. 14(Suppl 2): 53–65. 1999. View Article : Google Scholar : PubMed/NCBI
30.	Gnant M: Bisphosphonates in the prevention of disease recurrence: current results and ongoing trials. Curr Cancer Drug Targets. 9:824–833. 2009. View Article : Google Scholar : PubMed/NCBI
31.	Aft R, Naughton M, Trinkaus K, et al: Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol. 11:421–428. 2010. View Article : Google Scholar : PubMed/NCBI
32.	Saito H, Tsunenari T, Onuma E, Sato K, Ogata E and Yamada-Okabe H: Humanized monoclonal antibody against parathyroid hormone-related protein suppresses osteolytic bone metastasis of human breast cancer cells derived from MDA-MB-231. Anticancer Res. 25:3817–3824. 2005.
33.	Body JJ, Facon T, Coleman RE, et al: A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res. 12:1221–1228. 2006. View Article : Google Scholar : PubMed/NCBI